
Home » Izana Begins Trial of Rheumatoid Arthritis Drug for COVID-19
Izana Begins Trial of Rheumatoid Arthritis Drug for COVID-19

Izana Bioscience has initiated a two-center compassionate use study of its drug namilumab for treatment of patients with rapidly worsening COVID-19.
Namilumab is a human monoclonal antibody therapy that targets granulocyte-macrophage colony stimulating factor. It is currently in late-stage clinical development for the treatment of rheumatoid arthritis and ankylosing spondylitis.
Upcoming Events
-
08Sep
-
15Sep
-
20Sep
-
21Sep
-
22Sep
-
11Oct